Antithrombotic therapy in patients after ACS who have AF and are indicated for anticoagulation - Summary of recommendations and evidence
DOAC is preferable to warfarin	I	A
Clopidogrel is the preferred P2Y12 inhibitor, since it has been the most studied drug in this context	I	A
Triple therapy should be continued for the shortest possible time due to the high risk of associated bleeding.	IIa	A
When using warfarin, an INR between 2 and 2.5 is desirable.	IIa	C
ASA should be used in low doses, preferably ≤ 100 mg/day.	IIa	C
During hospitalization, triple therapy with ASA + P2Y12 inhibitor + anticoagulant should be used.	IIa	C
After hospital discharge, P2Y12 inhibitor and anticoagulant should be routinely continued for up to 12 months after the event. The P2Y12 inhibitor should be discontinued after 12 months, continuing only with the anticoagulant.	IIa	A
In patients with increased ischemic risk, triple therapy can be maintained for a longer period.	IIa	B
PPI should be considered the first choice as prophylaxis for stress ulcers due to the high risk of gastrointestinal bleeding.	IIa	C

INR: inInternationalormalized ratio